Beatrice Araújo Duarte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Beatrice Araújo Duarte has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Barroso Duarte
Hospital Universitário Walter Cantídio – Fortaleza (CE), Brazil
6 shared publications - João Vitor Araujo Duarte
Universidade Christus, Brasil
4 shared publications - Romélia Pinheiro Gonçalves Lemes
Universidade Federal do Ceará, Fortaleza, Brazil
4 shared publications - Isabella Araujo Duarte
University Center Christus
3 shared publications - Afonso Celso Vigorito
Universidade Estadual de Campinas – Campinas (SP), Brazil
2 shared publications - Anderson João Simione
Hospital Amaral Carvalho – Jaú (SP), Brazil
2 shared publications
Latest Publications
- 23 July 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (9)
Incidental Desmoplastic Small Round Cell Tumor During Appendectomy in a Pediatric Patient: A Rare Therapeutic Opportunity
- 23 July 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (9)
Incidental Desmoplastic Small Round Cell Tumor During Appendectomy in a Pediatric Patient: A Rare Therapeutic Opportunity
- Open Access
- 8 January 2026
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 7 (1)
The Brazilian Data Managers Working Group: a 10-year grassroots initiative for the development of the national hematopoietic cell transplantation and cellular therapy registry
Hematopoietic cell transplantation is a data-driven field, and reporting to outcomes registries has become a common practice worldwide. However, comprehensive transplant data collection requires dedicated professionals who can accurately capture data, follow international guidelines, and maintain reliable databases for the evaluation of transplant outcomes. This article describes the development and evolution of the Brazilian Data Managers Working Group (GTGD) and its contributions to professional education, collaborative networking, registry implementation, data quality improvement, and scientific engagement in hematopoietic cell transplantation and cellular therapy in Brazil. The transition from single-center reporting to the establishment of a national transplant registry required collaboration among centers, partnership between the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO) and the Center for International Blood and Marrow Transplant Research (CIBMTR), and the development of the GTGD to ensure the sustainability of this effort. The GTGD originated from a grassroots collaboration among data managers and transplant centers seeking to address limited professional recognition, inconsistent reporting practices, and restricted access to specialized training. Supported by collaboration with the SBTMO and CIBMTR, the initiative evolved into a nationally coordinated network. Over the decade, the GTGD promoted structured education, knowledge sharing, professional development, operational support, standardized data-management practices, quality-improvement initiatives, and scientific collaboration. In parallel, participation in the national multicenter protocol expanded to 95 centers, with 51 centers reporting data to the CIBMTR by 2025. The group also developed educational resources, supported benchmarking and cellular therapy reporting, strengthened national and international collaboration, and increased the visibility and professional identity of data managers within transplant programs. This experience demonstrates how coordinated engagement, continuous education, institutional collaboration, and professional advocacy can contribute to the development of national registry infrastructure and the generation of reliable real-world evidence in hematopoietic cell transplantation and cellular therapy.
- 8 January 2026
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 7 (1)
Open AccessThe Brazilian Data Managers Working Group: a 10-year grassroots initiative for the development of the national hematopoietic cell transplantation and cellular therapy registry
Hematopoietic cell transplantation is a data-driven field, and reporting to outcomes registries has become a common practice worldwide. However, comprehensive transplant data collection requires dedicated professionals who can accurately capture data, follow international guidelines, and maintain reliable databases for the evaluation of transplant outcomes. This article describes the development and evolution of the Brazilian Data Managers Working Group (GTGD) and its contributions to professional education, collaborative networking, registry implementation, data quality improvement, and scientific engagement in hematopoietic cell transplantation and cellular therapy in Brazil. The transition from single-center reporting to the establishment of a national transplant registry required collaboration among centers, partnership between the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO) and the Center for International Blood and Marrow Transplant Research (CIBMTR), and the development of the GTGD to ensure the sustainability of this effort. The GTGD originated from a grassroots collaboration among data managers and transplant centers seeking to address limited professional recognition, inconsistent reporting practices, and restricted access to specialized training. Supported by collaboration with the SBTMO and CIBMTR, the initiative evolved into a nationally coordinated network. Over the decade, the GTGD promoted structured education, knowledge sharing, professional development, operational support, standardized data-management practices, quality-improvement initiatives, and scientific collaboration. In parallel, participation in the national multicenter protocol expanded to 95 centers, with 51 centers reporting data to the CIBMTR by 2025. The group also developed educational resources, supported benchmarking and cellular therapy reporting, strengthened national and international collaboration, and increased the visibility and professional identity of data managers within transplant programs. This experience demonstrates how coordinated engagement, continuous education, institutional collaboration, and professional advocacy can contribute to the development of national registry infrastructure and the generation of reliable real-world evidence in hematopoietic cell transplantation and cellular therapy.
- Open Access
- 8 January 2026
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 7 (1)
Outcomes of hematopoietic stem-cell transplantation in infants with KMT2A-rearranged acute lymphoblastic leukemia in first remission: a systematic review and single-arm meta-analysis
Infants with acute lymphoblastic leukemia (ALL) frequently experience poor outcomes, with KMT2A gene rearrangements (KMT2A-r) serving as the most significant adverse prognostic factor. Allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission (CR1) has been utilized to improve survival, yet its definitive role remains a subject of intense debate. This systematic review and meta-analysis aimed to evaluate survival outcomes of HSCT in infants with KMT2A-r ALL in CR1. We systematically searched PubMed, Embase, and the Cochrane Library for randomized and observational studies reporting survival outcomes for infants with KMT2A-r ALL undergoing HSCT in CR1. Survival data were synthesized using parametric modeling (Weibull distribution) to estimate pooled outcomes. Mean survival across 1,000 iterations per study was calculated with 95%CI. Heterogeneity was assessed using IÇ statistics. All analyses were performed using R software (version 4.1.3). Seven studies comprising 371 patients were included. The pooled analysis demonstrated a 4-year overall survival (OS) of 65% (95%CI 58.7-72.1), a 4-year disease-free survival of 57.5% (95%CI 51.8-64.3), and a 3-year event-free survival (EFS) of 53.2% (95%CI 41.5-66.1). Our findings suggest that HSCT in CR1 is a viable therapeutic strategy for selected high-risk infants with KMT2A-r ALL, showing improved survival compared to historical benchmarks. While novel and safer therapies are currently under investigation, HSCT remains a reasonable option. Clinical decisions should carefully balance the curative potential of transplantation against the risk of severe treatment-related toxicities and long-term sequelae.
- 8 January 2026
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 7 (1)
Open AccessOutcomes of hematopoietic stem-cell transplantation in infants with KMT2A-rearranged acute lymphoblastic leukemia in first remission: a systematic review and single-arm meta-analysis
Infants with acute lymphoblastic leukemia (ALL) frequently experience poor outcomes, with KMT2A gene rearrangements (KMT2A-r) serving as the most significant adverse prognostic factor. Allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission (CR1) has been utilized to improve survival, yet its definitive role remains a subject of intense debate. This systematic review and meta-analysis aimed to evaluate survival outcomes of HSCT in infants with KMT2A-r ALL in CR1. We systematically searched PubMed, Embase, and the Cochrane Library for randomized and observational studies reporting survival outcomes for infants with KMT2A-r ALL undergoing HSCT in CR1. Survival data were synthesized using parametric modeling (Weibull distribution) to estimate pooled outcomes. Mean survival across 1,000 iterations per study was calculated with 95%CI. Heterogeneity was assessed using IÇ statistics. All analyses were performed using R software (version 4.1.3). Seven studies comprising 371 patients were included. The pooled analysis demonstrated a 4-year overall survival (OS) of 65% (95%CI 58.7-72.1), a 4-year disease-free survival of 57.5% (95%CI 51.8-64.3), and a 3-year event-free survival (EFS) of 53.2% (95%CI 41.5-66.1). Our findings suggest that HSCT in CR1 is a viable therapeutic strategy for selected high-risk infants with KMT2A-r ALL, showing improved survival compared to historical benchmarks. While novel and safer therapies are currently under investigation, HSCT remains a reasonable option. Clinical decisions should carefully balance the curative potential of transplantation against the risk of severe treatment-related toxicities and long-term sequelae.
- Open Access
- 26 June 2025
- Published by Wiley in European Journal of Haematology
- Vol. 115 (4) , 349-357
Outcomes After Allogeneic Hematopoietic Cell Transplantation in Adults With Myelodysplastic Syndrome With 65 Years or Older Compared to Youngers. A Retrospective Analysis of the Latin America Registry
This retrospective multicenter study aimed to compare outcomes and evaluate risks associated with allogeneic hematopoietic cell transplantation (allo‐HCT) in myelodysplastic syndrome patients aged ≥ 65 versus < 65 years in Latin America, across 38 transplant centers (1988–2023). Of the 441 patients, 70 (16%) were ≥ 65 years (median age 68 ± 3.7). At 5 years, overall survival (OS) was 49.3% in patients ≥ 65 vs. 56.7% in those < 65 (p = 0.49), and progression‐free survival (PFS) was 48.4% vs. 56.2% (p = 0.40). The cumulative incidence of relapse was 13.6%, and non‐relapse mortality (NRM) 33.8%. After propensity score matching, no significant differences were observed between the age groups in OS (HR = 1.16; 95% CI: 0.76–1.77; p = 0.488), NRM (HR = 1.03; 95% CI: 0.64–1.67; p = 0.90) or PFS (HR = 1.20; 95% CI: 0.779–1.83; p = 0.40). PFS in patients ≥ 65 years was associated with high‐risk IPSS‐R stratification (p = 0.0056). The age group ≥ 65 years conferred higher risk of relapse compared to patients aged < 65 years (HR = 2.77; 95% CI: 1.07–7.15; p = 0.035). In patients ≥ 65 years, prevalence risk was associated to male sex, reduced‐intensity conditioning, mobilized blood cells, and prior treatment, while in those < 65 years, to complications and chronic GVHD (p < 0.05). HCT is feasible in elderly patients. However, age may influence disease progression in very high‐risk elderly patients and risk of relapse after transplantation.
- 26 June 2025
- Published by Wiley in European Journal of Haematology
- Vol. 115 (4) , 349-357
Open AccessOutcomes After Allogeneic Hematopoietic Cell Transplantation in Adults With Myelodysplastic Syndrome With 65 Years or Older Compared to Youngers. A Retrospective Analysis of the Latin America Registry
This retrospective multicenter study aimed to compare outcomes and evaluate risks associated with allogeneic hematopoietic cell transplantation (allo‐HCT) in myelodysplastic syndrome patients aged ≥ 65 versus < 65 years in Latin America, across 38 transplant centers (1988–2023). Of the 441 patients, 70 (16%) were ≥ 65 years (median age 68 ± 3.7). At 5 years, overall survival (OS) was 49.3% in patients ≥ 65 vs. 56.7% in those < 65 (p = 0.49), and progression‐free survival (PFS) was 48.4% vs. 56.2% (p = 0.40). The cumulative incidence of relapse was 13.6%, and non‐relapse mortality (NRM) 33.8%. After propensity score matching, no significant differences were observed between the age groups in OS (HR = 1.16; 95% CI: 0.76–1.77; p = 0.488), NRM (HR = 1.03; 95% CI: 0.64–1.67; p = 0.90) or PFS (HR = 1.20; 95% CI: 0.779–1.83; p = 0.40). PFS in patients ≥ 65 years was associated with high‐risk IPSS‐R stratification (p = 0.0056). The age group ≥ 65 years conferred higher risk of relapse compared to patients aged < 65 years (HR = 2.77; 95% CI: 1.07–7.15; p = 0.035). In patients ≥ 65 years, prevalence risk was associated to male sex, reduced‐intensity conditioning, mobilized blood cells, and prior treatment, while in those < 65 years, to complications and chronic GVHD (p < 0.05). HCT is feasible in elderly patients. However, age may influence disease progression in very high‐risk elderly patients and risk of relapse after transplantation.
- 24 November 2020
- Published by Sociedade Brasileira de Computação
- p. 509-513
Ferramenta de Prototipagem para Criação de um Aplicativo para o Ensino na Saúde
O isolamento social alterou a rotina de muitas instituições de ensino que buscam, nas tecnologias, uma solução para dar continuidade ao processo pedagógico. Todavia, percebe-se escassez desses recursos nos cursos da área da saúde. O presente trabalho tem como objetivo analisar a aplicação do Figma durante a criação de um aplicativo educativo para o ensino hematológico no curso de medicina. O estudo segue uma abordagem qualitativa, do tipo pesquisa-ação. Constatou-se que a ferramenta possibilita interação, compartilhamento de informações e um ótimo espaço de colaboração.
- 24 November 2020
- Published by Sociedade Brasileira de Computação
- p. 509-513
Ferramenta de Prototipagem para Criação de um Aplicativo para o Ensino na Saúde
O isolamento social alterou a rotina de muitas instituições de ensino que buscam, nas tecnologias, uma solução para dar continuidade ao processo pedagógico. Todavia, percebe-se escassez desses recursos nos cursos da área da saúde. O presente trabalho tem como objetivo analisar a aplicação do Figma durante a criação de um aplicativo educativo para o ensino hematológico no curso de medicina. O estudo segue uma abordagem qualitativa, do tipo pesquisa-ação. Constatou-se que a ferramenta possibilita interação, compartilhamento de informações e um ótimo espaço de colaboração.
- Open Access
- 1 October 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (10) , 1335-1337
Renal changes in COVID-19 infection
SUMMARY The COVID-19 (SARS-CoV-2) infection started in China, Wuhan City, Hubei Province, in December 2019, and it was declared a pandemic in mid-March 2020, caused by a new coronavirus strain called SARS-CoV-2. The pathogenesis of kidney injury attributed to SARS- CoV-2 is not well defined yet. Observations show that the kidney damage caused by the new virus mutation is mainly tubular, with impairment of glomerular filtration and high levels of urea and creatinine. A study with seriously ill patients with COVID-19 showed that acute kidney injury was present in 29%. In the face of this evidence, based on recent studies, we can see the great renal contribution as an impact factor in the evolution of COVID-19, not just as a complicator of severity, but maybe part of the initial cascade of the process, requiring a deeper analysis using conventional biomarkers of kidney injury and more aggressive clinical intervention in patients at risk, in an attempt to reduce mortality.
- 1 October 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (10) , 1335-1337
Open AccessRenal changes in COVID-19 infection
SUMMARY The COVID-19 (SARS-CoV-2) infection started in China, Wuhan City, Hubei Province, in December 2019, and it was declared a pandemic in mid-March 2020, caused by a new coronavirus strain called SARS-CoV-2. The pathogenesis of kidney injury attributed to SARS- CoV-2 is not well defined yet. Observations show that the kidney damage caused by the new virus mutation is mainly tubular, with impairment of glomerular filtration and high levels of urea and creatinine. A study with seriously ill patients with COVID-19 showed that acute kidney injury was present in 29%. In the face of this evidence, based on recent studies, we can see the great renal contribution as an impact factor in the evolution of COVID-19, not just as a complicator of severity, but maybe part of the initial cascade of the process, requiring a deeper analysis using conventional biomarkers of kidney injury and more aggressive clinical intervention in patients at risk, in an attempt to reduce mortality.
- Open Access
- 1 May 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (5) , 571-572
Hemostasis profile in COVID-19 infection
According to some current studies, the infection by COVID-19 (SARS- CoV-2) appears to be associated with the involvement of hemostasis in the Chinese population, developing to Acute Respiratory Distress Syndrome (ARDS). The context reported here focuses on cases with ARDS, which has been implicated with the presence of an endothelial lesion, production of pro-coagulating factors, and generation of fibrin degradation product (D-dimer), compatible with disseminated intravascular coagulation (DIC).1 The increase in the concentration of D-dimer 3-4 times above the normal levels was associated with the outcome of death and there are reports of thromboembolic phenomena, and factors of worse prognosis, such as advanced age, low immunity, neutrophilia, and organ and coagulation dysfunction.2 Patients who develop a more severe response to the disease may evolve to dyspnea and hypoxemia within one week from the onset of the disease and may progress rapidly to ARDS or target organ failure. Among other possibilities, coagulation, in the cases that have been reported in the literature, consists of prolonged prothrombin time (PT) and partial activated thromboplastin time (APTT) in 2.1% and 9.7%, respectively, of the patients who had ARDS. Epidemiological data report that changes in coagulation, in COVID-19 infections, associated with ARDS and the systemic inflammatory process, may react releasing a large amount of pro-inflammatory cytokines - tumor necrosis factor, interleukin (IL) -1, IL -6 and IL-8 - although the pathogenesis of human COVID19 has not yet been fully clarified. Studies reinforce the hypothesis that the great increase in the production of cytokines is associated with a deficient immune system and are the two main triggers of events that culminate in the serious evolution of the infection.1 , 2 In this context, it is important to develop preventive measures, as well as laboratory tests and early prognostic markers of patients who will present the severe form, so that a therapeutic approach is performed in the initial phase in patients affected by COVID-19. This way, it will be possible to avoid the evolution to death in this group of patients, since the course of the disease can be quick, progressing to ARDS within one week from the onset of the disease, in addition to target organ failure.2 Comparing the laboratory tests of patients with and without ARDS, it was noticed that the group with ARDS had significant changes in index values, i.e., liver injury, renal dysfunction, related to inflammation and coagulation function. Also, the lymphocyte count and CD8 T cells were significantly decreased. In addition to this worrying matter, patients who developed ARDS did not respond well to treatments with antiretrovirals.2 Given these facts, it is of utmost importance to evaluate the benefit laboratory tests and prognostic markers, on hospital admission, could bring to favor those patients who will evolve to the severe form, aiming at early preventive and therapeutic measures, to avoid evolution to unfavorable outcomes. Among the important tests so far, we can mention blood count, PT, APTT, and D-dimer, which have all been mentioned and whose correlations were observed in the literature as prognostic markers, as follows: severe lymphopenia, neutrophilia, and thrombocytopenia at the complete blood count; extended PT and increased D-dimer are associated with cases of severe evolution.3 - 5 However, the guidance to patients who were already using oral anticoagulant medications, before contracting COVID-19, is to continue with the treatment; however, greater laboratory and clinical monitoring of these patients is necessary, as recommended by Chinese studies that note that altered PT, even at mild levels, is also a factor of poor prognosis and reinforce that, in this scenario, the patient/control relationship should be used instead of the INR.
- 1 May 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (5) , 571-572
Open AccessHemostasis profile in COVID-19 infection
According to some current studies, the infection by COVID-19 (SARS- CoV-2) appears to be associated with the involvement of hemostasis in the Chinese population, developing to Acute Respiratory Distress Syndrome (ARDS). The context reported here focuses on cases with ARDS, which has been implicated with the presence of an endothelial lesion, production of pro-coagulating factors, and generation of fibrin degradation product (D-dimer), compatible with disseminated intravascular coagulation (DIC).1 The increase in the concentration of D-dimer 3-4 times above the normal levels was associated with the outcome of death and there are reports of thromboembolic phenomena, and factors of worse prognosis, such as advanced age, low immunity, neutrophilia, and organ and coagulation dysfunction.2 Patients who develop a more severe response to the disease may evolve to dyspnea and hypoxemia within one week from the onset of the disease and may progress rapidly to ARDS or target organ failure. Among other possibilities, coagulation, in the cases that have been reported in the literature, consists of prolonged prothrombin time (PT) and partial activated thromboplastin time (APTT) in 2.1% and 9.7%, respectively, of the patients who had ARDS. Epidemiological data report that changes in coagulation, in COVID-19 infections, associated with ARDS and the systemic inflammatory process, may react releasing a large amount of pro-inflammatory cytokines - tumor necrosis factor, interleukin (IL) -1, IL -6 and IL-8 - although the pathogenesis of human COVID19 has not yet been fully clarified. Studies reinforce the hypothesis that the great increase in the production of cytokines is associated with a deficient immune system and are the two main triggers of events that culminate in the serious evolution of the infection.1 , 2 In this context, it is important to develop preventive measures, as well as laboratory tests and early prognostic markers of patients who will present the severe form, so that a therapeutic approach is performed in the initial phase in patients affected by COVID-19. This way, it will be possible to avoid the evolution to death in this group of patients, since the course of the disease can be quick, progressing to ARDS within one week from the onset of the disease, in addition to target organ failure.2 Comparing the laboratory tests of patients with and without ARDS, it was noticed that the group with ARDS had significant changes in index values, i.e., liver injury, renal dysfunction, related to inflammation and coagulation function. Also, the lymphocyte count and CD8 T cells were significantly decreased. In addition to this worrying matter, patients who developed ARDS did not respond well to treatments with antiretrovirals.2 Given these facts, it is of utmost importance to evaluate the benefit laboratory tests and prognostic markers, on hospital admission, could bring to favor those patients who will evolve to the severe form, aiming at early preventive and therapeutic measures, to avoid evolution to unfavorable outcomes. Among the important tests so far, we can mention blood count, PT, APTT, and D-dimer, which have all been mentioned and whose correlations were observed in the literature as prognostic markers, as follows: severe lymphopenia, neutrophilia, and thrombocytopenia at the complete blood count; extended PT and increased D-dimer are associated with cases of severe evolution.3 - 5 However, the guidance to patients who were already using oral anticoagulant medications, before contracting COVID-19, is to continue with the treatment; however, greater laboratory and clinical monitoring of these patients is necessary, as recommended by Chinese studies that note that altered PT, even at mild levels, is also a factor of poor prognosis and reinforce that, in this scenario, the patient/control relationship should be used instead of the INR.
- Open Access
- 1 May 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (5) , 580-582
Immunohistochemistry contribution in the diagnosis of splenic marginal zone lymphoma
Splenic marginal zone B-cell lymphoma is a rare type of non-Hodgkin B-cell lymphoma, without preference for sex, which affects individuals mainly over 50 years. In many cases, the disease is asymptomatic, with absent splenomegaly and lymphadenomegaly. The changes in the peripheral blood, when present, are lymphocytosis, anemia, and thrombocytopenia; cytopenias are mostly due to hypersplenism. The presence of B symptoms and increased LDH is rare1 , 2 . The immunophenotype pattern is characterized by pan-B cell expression with positive CD19, CD20, CD22, CD79a, IgM, and IgD. CD5 is found only in 15%, and CD23 in 30% of cases. It presents as the most common cytogenetic alteration the heterogeneous expressions of chromosome 7, the (9:14) (p13: q32), which overlaps the IgH and PAX-53 genes. The marrow infiltration patterns are highly variable and consist of nodular, paratrabecular, and interstitial4 , 5 . The finding of the intrasinusoidal pattern is more easily observed by CD20 or CD34 immunohistochemistry. Spleen histology shows micronodular infiltration of white pulp with biphasic pattern and a variable degree of red pulp involvement. Differential diagnosis should be made with other chronic B7 cell lymphoproliferative diseases5 .
- 1 May 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (5) , 580-582
Open AccessImmunohistochemistry contribution in the diagnosis of splenic marginal zone lymphoma
Splenic marginal zone B-cell lymphoma is a rare type of non-Hodgkin B-cell lymphoma, without preference for sex, which affects individuals mainly over 50 years. In many cases, the disease is asymptomatic, with absent splenomegaly and lymphadenomegaly. The changes in the peripheral blood, when present, are lymphocytosis, anemia, and thrombocytopenia; cytopenias are mostly due to hypersplenism. The presence of B symptoms and increased LDH is rare1 , 2 . The immunophenotype pattern is characterized by pan-B cell expression with positive CD19, CD20, CD22, CD79a, IgM, and IgD. CD5 is found only in 15%, and CD23 in 30% of cases. It presents as the most common cytogenetic alteration the heterogeneous expressions of chromosome 7, the (9:14) (p13: q32), which overlaps the IgH and PAX-53 genes. The marrow infiltration patterns are highly variable and consist of nodular, paratrabecular, and interstitial4 , 5 . The finding of the intrasinusoidal pattern is more easily observed by CD20 or CD34 immunohistochemistry. Spleen histology shows micronodular infiltration of white pulp with biphasic pattern and a variable degree of red pulp involvement. Differential diagnosis should be made with other chronic B7 cell lymphoproliferative diseases5 .
- Open Access
- 1 February 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (2) , 99
Hematological changes in Covid-19 infections
The complete blood count is the test used to approach infections that are very prevalent in Brasil, with emphasis on arboviruses, especially Dengue. The exam assesses hematopoietic lineage from a quantitative and qualitative viewpoint. In the Chinese population, studies have reported the presence of leukopenia on hospital admission, basically at the expense of moderate to severe lymphopenia and mild thrombocytopenia 2. The review of studies that contained analyses of peripheral blood samples showed that a greater number of lymphopenic patients had the presence of reactive lymphocytes, of which a subset appeared to be lymphoplasmacytoid 2. Thus, the monitoring of these hematological parameters is essential and can assist in the identification of patients who will need care in the Intensive care unit, as they presented a deeper lymphopenia, as well as a decrease in hemoglobin, absolute monocyte count and even tend to develop neutrophilia during hospitalization, with a peak in this period of ICU stay [FAN et al., 2020]. The presence of atypical or activated lymphocytes is not significant for the degree of infection, the main comorbidity of which is Acute Respiratory Distress Syndrome (ARDS). This contrasts with what is observed in severe dengue during the admission of patients from a referral hospital of Fortaleza, Brasil, and this parameter can have a screening function as a modulator of the evolution of the viral process in arboviruses 1. The non-alteration of the erythroid lineage, such as hemoconcentration and a slight numerical alteration of platelets, when present, also contrasts with severe dengue 1. Lymphopenia, which has also been documented in chikungunya 3, in covid-19, seems to be the most relevant peripheral hematopoietic alteration, its use being suggested as a severity biomarker of the infection. In this context, studies related to the evaluation of biomarkers of hematological parameters that can be used as screening for exam diagnosis, as well as monitoring the evolution of severe cases, when necessary.
- 1 February 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (2) , 99
Open AccessHematological changes in Covid-19 infections
The complete blood count is the test used to approach infections that are very prevalent in Brasil, with emphasis on arboviruses, especially Dengue. The exam assesses hematopoietic lineage from a quantitative and qualitative viewpoint. In the Chinese population, studies have reported the presence of leukopenia on hospital admission, basically at the expense of moderate to severe lymphopenia and mild thrombocytopenia 2. The review of studies that contained analyses of peripheral blood samples showed that a greater number of lymphopenic patients had the presence of reactive lymphocytes, of which a subset appeared to be lymphoplasmacytoid 2. Thus, the monitoring of these hematological parameters is essential and can assist in the identification of patients who will need care in the Intensive care unit, as they presented a deeper lymphopenia, as well as a decrease in hemoglobin, absolute monocyte count and even tend to develop neutrophilia during hospitalization, with a peak in this period of ICU stay [FAN et al., 2020]. The presence of atypical or activated lymphocytes is not significant for the degree of infection, the main comorbidity of which is Acute Respiratory Distress Syndrome (ARDS). This contrasts with what is observed in severe dengue during the admission of patients from a referral hospital of Fortaleza, Brasil, and this parameter can have a screening function as a modulator of the evolution of the viral process in arboviruses 1. The non-alteration of the erythroid lineage, such as hemoconcentration and a slight numerical alteration of platelets, when present, also contrasts with severe dengue 1. Lymphopenia, which has also been documented in chikungunya 3, in covid-19, seems to be the most relevant peripheral hematopoietic alteration, its use being suggested as a severity biomarker of the infection. In this context, studies related to the evaluation of biomarkers of hematological parameters that can be used as screening for exam diagnosis, as well as monitoring the evolution of severe cases, when necessary.